ABVC BioPharma

Another informative interview from our CEO, Dr. Uttam Patil

Integrating Botanical Drugs into Western Medicine Uttam Patil, CEO of ABVC BioPharma, joins Biotech Orbit to talk about the complex path of developing botanical drugs within modern regulatory systems.Botanic...

Another great interview by our CEO, Dr. Uttam Patil, by the Wall Street Reporter.

ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil discussing the company's drug development pipeline, and upcoming milestones. Join this channel t...

Amazing to see our CEO, Uttam Patil, featured in this episode!

Indian Talent in Taiwan: Opportunities, Experiences, and the Employment Gold Card | Namaste Taiwan Lots of Indians work and study in Taiwan! Dr. Priya is visiting some students and professionals currently working in Taiwan to see how they feel about their ...

Meet our CEO.
One of the top 10 CEO's in Taiwan according to CEO Insights magazine.

"This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life."

ABVC - ABVC BioPharma's CEO Discusses New Drug Development... --News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder ABVC BioPharma Inc..

After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC Biopharma Inc (NASDAQ:ABVC). and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients.

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. ...

All-Natural Treatment for Major Depressive Disorder (MDD) Explained. Struggling with MDD? Discover how ABV-1504, an all-natural solution, can help manage symptoms effectively without severe adverse side effects. This video introduces the challenges of living with MDD and highlights the benefits of our innovative treatment. Learn more about how ABV-1504 can improve your mental health naturally and safely. Watch now to find out more!

All Natural Treatment for MDD ABV-1504 All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504 Explained. Struggling with MDD? Discover how ABV-1504, an all-natural solution, can help...

"We believe that our combined expertise in biopharmaceuticals and AI technology will enable us to develop more effective treatments for depression in cancer patients, ultimately improving their quality of life." - from our C.E.O.

ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI FREMONT, CA - (NewMediaWire) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that afte...

ABVC moving forward in the market.

ABVC BioPharma Benefits from Lucrative Licensing Deal - BourseWatch - Latest Daily Stock Market And Finance News ABVC BioPharma, Inc. has strategically concluded licensing agreements for all its pipelines, a significantachievement that underscores its commitment to

We would like to congratulate our subsidiary AiBtl on their acquisition of TTLife.

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, an...

Great news out this morning
"Having this land will allow AVBC and AIBL to save costs in the future by having their controlled-condition farm to grow the Botanicals and maintain quality, which will be critical for our medications. "

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl ...

What a great way to start the new year. Read our huge announcement made this morning.

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology,...